Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Auteurs principaux: V. I. Ignatyeva (Auteur), S. V. Moiseev (Auteur), N. M. Bulanov (Auteur), E. A. Karovajkina (Auteur), A S. Moiseev (Auteur)
• Format: Livre
• Publié: IRBIS LLC, 2019-01-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...